X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-03 | IONS | Ionis Pharmaceuticals Inc | Loscalzo Joseph | Dir | S - Sale+OE | $80.26 | -1,032 | 36,330 | -3% | -$82,833 | |||||
| D | 2026-03-03 | IONS | Ionis Pharmaceuticals Inc | Klein Joseph III | Dir | S - Sale+OE | $79.51 | -21,332 | 11,114 | -66% | -$1,696,181 | |||||
| D | 2026-03-03 | IONS | Ionis Pharmaceuticals Inc | Diaz Allene M. | Dir | S - Sale+OE | $79.35 | -54,878 | 3,811 | -94% | -$4,354,428 | |||||
| D | 2026-03-03 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale+OE | $79.40 | -20,106 | 22,541 | -47% | -$1,596,433 | |||||
| D | 2026-03-03 | IONS | Ionis Pharmaceuticals Inc | Bennett C Frank | EVP, Chief Scientific Officer | S - Sale+OE | $79.23 | -85,089 | 80,554 | -51% | -$6,741,669 | |||||
| DM | 2026-03-03 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $79.74 | -6,659 | 45,664 | -13% | -$530,987 | |||||
| D | 2026-03-05 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale+OE | $75.50 | -7,312 | 185,543 | -4% | -$552,031 | |||||
2026-03-04 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | CEO, 10% | P - Purchase | $4.26 | +10,000 | 1,138,241 | +1% | +$42,560 | ||||||
| D | 2026-03-05 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $483.16 | -8,300 | 36,844 | -18% | -$4,010,187 | |||||
| D | 2026-03-04 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $317.97 | -19,000 | 639,489 | -3% | -$6,041,414 | |||||
| D | 2026-03-04 | UTHR | United Therapeutics Corp | Kurzweil Ray | Dir | S - Sale+OE | $489.02 | -4,910 | 12,670 | -28% | -$2,401,088 | |||||
| D | 2026-03-04 | UTHR | United Therapeutics Corp | Thompson Tommy G | Dir | S - Sale+OE | $489.42 | -2,000 | 22,480 | -8% | -$978,839 | |||||
| D | 2026-03-04 | UTHR | United Therapeutics Corp | Causey Christopher | Dir | S - Sale+OE | $490.17 | -20 | 4,190 | 0% | -$9,803 | |||||
| D | 2026-03-03 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $499.42 | -9,500 | 639,489 | -1% | -$4,744,467 | |||||
2026-03-03 | COLL | Collegium Pharmaceutical, Inc | Dreyer Scott | EVP, Chief Commercial Officer | S - Sale | $40.41 | -49,976 | 71,770 | -41% | -$2,019,437 | ||||||
| D | 2026-03-05 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $61.87 | -26,000 | 65,440 | -28% | -$1,608,730 | |||||
| D | 2026-03-05 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $146.03 | -10,699 | 535,109 | -2% | -$1,562,328 | |||||
| D | 2026-03-03 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, Europe Commercial | S - Sale+OE | $32.36 | -128,985 | 123,127 | -51% | -$4,173,942 | |||||
2026-03-03 | AGIO | Agios Pharmaceuticals, Inc. | Washburn Theodore James Jr. | Principal Accounting Officer | S - Sale | $28.88 | -5,272 | 868 | -86% | -$152,255 | ||||||
2026-03-03 | ZLAB | Zai Lab Ltd | Amado Rafael | See Remarks | S - Sale | $17.38 | -10,000 | 42,391 | -19% | -$173,800 | ||||||
| D | 2026-03-03 | TEVA | Teva Pharmaceutical Industries Ltd | Savage Brian | Interim GC | S - Sale+OE | $32.36 | -1,274 | 2,926 | -30% | -$41,227 | |||||
| M | 2026-03-03 | HROW | Harrow, Inc. | Opaleye Management Inc. | 10% | S - Sale | $39.51 | -198,572 | 3,681,428 | -5% | -$7,846,426 | |||||
| D | 2026-03-03 | TEVA | Teva Pharmaceutical Industries Ltd | Francis Richard D | Pres, CEO | S - Sale+OE | $32.36 | -442,935 | 1,121,382 | -28% | -$14,333,332 | |||||
| D | 2026-03-03 | TEVA | Teva Pharmaceutical Industries Ltd | Hughes Eric A | See "Remarks" | S - Sale+OE | $32.36 | -80,762 | 85,616 | -49% | -$2,613,450 | |||||
| D | 2026-03-03 | LGND | Ligand Pharmaceuticals Inc | Sabba Stephen L | Dir | S - Sale+OE | $201.50 | -2,034 | 33,793 | -6% | -$409,851 | |||||
2026-03-04 | FBLG | Fibrobiologics, Inc. | Khoja Hamid | CHIEF SCIENTIFIC OFFICER | P - Purchase | $0.38 | +30,000 | 61,250 | +96% | +$11,400 | ||||||
2026-03-02 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $200.50 | -467 | 42,720 | -1% | -$93,632 | ||||||
| D | 2026-03-02 | ALKS | Alkermes Plc. | Parisi Samuel Joseph | VP, Finance (Interim PAO) | S - Sale+OE | $29.29 | -6,890 | 7,717 | -47% | -$201,808 | |||||
| D | 2026-03-02 | ALKS | Alkermes Plc. | Nichols Christian Todd | SVP, Chief Commercial Officer | S - Sale+OE | $30.00 | -6,000 | 109,769 | -5% | -$180,000 | |||||
| D | 2026-03-02 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $29.72 | -9,000 | 89,389 | -9% | -$267,485 | |||||
| DM | 2026-03-02 | ALKS | Alkermes Plc. | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S - Sale+OE | $29.53 | -4,068 | 235,626 | -2% | -$120,108 | |||||
2026-03-02 | FOLD | Amicus Therapeutics, Inc. | Campbell Bradley L | Pres, CEO | S - Sale | $14.35 | -22,500 | 998,680 | -2% | -$322,839 | ||||||
| D | 2026-03-03 | XNCR | Xencor Inc | Desjarlais John R | SVP, CSO | S - Sale+OE | $11.90 | -2,663 | 270,451 | -1% | -$31,677 | |||||
| D | 2026-03-03 | XNCR | Xencor Inc | Eckert Celia | SVP, GC | S - Sale+OE | $11.90 | -1,492 | 81,929 | -2% | -$17,747 | |||||
| D | 2026-03-03 | XNCR | Xencor Inc | Dahiyat Bassil I | Pres, CEO | S - Sale+OE | $11.90 | -6,758 | 567,792 | -1% | -$80,387 | |||||
| D | 2026-03-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Poulton Jeffrey V. | EVP, CFO | S - Sale+OE | $327.65 | -2,206 | 64,330 | -3% | -$722,801 | |||||
| DM | 2026-03-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Garg Pushkal | EVP Chief R, D | S - Sale+OE | $323.63 | -3,492 | 24,087 | -13% | -$1,130,131 | |||||
| DM | 2026-03-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale+OE | $323.62 | -3,250 | 22,397 | -13% | -$1,051,773 | |||||
| D | 2026-03-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Tanguler Tolga | EVP, Chief Commercial Officer | S - Sale+OE | $327.65 | -1,598 | 36,606 | -4% | -$523,584 | |||||
| D | 2026-03-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Greenstreet Yvonne | CEO | S - Sale+OE | $327.65 | -6,799 | 99,035 | -6% | -$2,227,698 | |||||
| D | 2026-03-02 | SEPN | Septerna, Inc. | Shaikhly Samira | Chief People Officer | S - Sale+OE | $28.10 | -70,453 | 793 | -99% | -$1,979,838 | |||||
2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Williams Timothy | SVP, GC | S - Sale | $8.27 | -42,434 | 377,450 | -10% | -$350,755 | ||||||
2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treasurer | S - Sale | $8.27 | -42,442 | 412,015 | -9% | -$350,821 | ||||||
2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Wijkstrom Joakim | SVP, CMO | S - Sale | $8.27 | -30,800 | 333,469 | -8% | -$254,590 | ||||||
2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Polymeropoulos Mihael Hristos | Pres, CEO | S - Sale | $8.17 | -156,235 | 2,704,496 | -5% | -$1,276,971 | ||||||
2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | S - Sale | $8.27 | -42,431 | 494,197 | -8% | -$350,730 | ||||||
2026-03-02 | ANIP | Ani Pharmaceuticals Inc | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $74.00 | -417 | 103,508 | 0% | -$30,858 | ||||||
2026-03-03 | ANIP | Ani Pharmaceuticals Inc | Gutwerg Ori | SVP, GENERICS | S - Sale | $76.50 | -2,060 | 84,782 | -2% | -$157,590 | ||||||
| M | 2026-03-02 | PMN | Promis Neurosciences Inc. | Williams Eugene | Dir | P - Purchase | $23.11 | +4,000 | 10,397 | +63% | +$92,420 | |||||
| M | 2026-03-02 | FBLG | Fibrobiologics, Inc. | O'Heeron Pete | CEO | P - Purchase | $0.38 | +51,500 | 5,958,147 | +1% | +$19,531 | |||||
2026-03-03 | CRNX | Crinetics Pharmaceuticals, Inc. | Okey Stephanie | Dir | S - Sale | $39.67 | -3,000 | 13,300 | -18% | -$119,010 | ||||||
2026-03-03 | CRNX | Crinetics Pharmaceuticals, Inc. | Schilke Tobin | CFO | S - Sale | $39.67 | -6,713 | 78,121 | -8% | -$266,305 | ||||||
2026-03-02 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $6.25 | -16,667 | 1,226,507 | -1% | -$104,086 | ||||||
2026-03-02 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $46.78 | -34,791 | 194,899 | -15% | -$1,627,534 | ||||||
2026-03-03 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | CEO, 10% | P - Purchase | $3.63 | +10,000 | 1,128,241 | +1% | +$36,300 | ||||||
2026-03-02 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $65.88 | -7,378 | 85,211 | -8% | -$486,069 | ||||||
2026-03-02 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, MD | S - Sale | $9.95 | -34,437 | 604,639 | -5% | -$342,648 | ||||||
| D | 2026-03-02 | KNSA | Kiniksa Pharmaceuticals International, Plc | Paolini John F. | CHIEF MEDICAL OFFICER | S - Sale+OE | $44.82 | -40,000 | 61,324 | -39% | -$1,792,940 | |||||
2026-03-02 | QURE | Uniqure N.V. | Klemt Christian | CFO | S - Sale | $9.95 | -12,532 | 198,981 | -6% | -$124,693 | ||||||
2026-03-02 | QURE | Uniqure N.V. | Potts Jeannette | GC | S - Sale | $9.95 | -8,578 | 106,495 | -7% | -$85,351 | ||||||
2026-03-02 | ANNX | Annexon, Inc. | Dananberg Jamie | Chief Medical Officer | S - Sale | $5.43 | -5,820 | 123,582 | -4% | -$31,603 | ||||||
2026-03-02 | ANNX | Annexon, Inc. | Overdorf Michael | EVP, CHIEF BUSINESS OFFICER | S - Sale | $5.42 | -4,339 | 182,625 | -2% | -$23,517 | ||||||
2026-03-02 | ANNX | Annexon, Inc. | Yednock Ted | EVP, CHIEF INNOVATION OFFICER | S - Sale | $5.42 | -5,566 | 154,161 | -3% | -$30,168 | ||||||
2026-03-02 | ANNX | Annexon, Inc. | Artis Dean Richard | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $5.43 | -5,894 | 180,093 | -3% | -$32,004 | ||||||
2026-03-02 | ANNX | Annexon, Inc. | Lew Jennifer | EVP, CFO | S - Sale | $5.42 | -5,565 | 170,700 | -3% | -$30,162 | ||||||
2026-03-02 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Smethurst Dominic | Chief Medical Officer | S - Sale | $8.30 | -6,097 | 89,790 | -6% | -$50,601 | ||||||
2026-03-02 | STOK | Stoke Therapeutics, Inc. | Krainer Adrian R. | Dir | S - Sale | $39.66 | -7,229 | 316,545 | -2% | -$286,715 | ||||||
2026-03-02 | QURE | Uniqure N.V. | Abi-Saab Walid | Chief Medical Officer | S - Sale | $9.95 | -1,660 | 148,777 | -1% | -$16,517 | ||||||
2026-03-03 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $186.44 | -6,000 | 405,796 | -1% | -$1,118,613 | ||||||
2026-03-02 | VRTX | Vertex Pharmaceuticals Inc / Ma | Liu Joy | EVP, GC | S - Sale | $495.96 | -892 | 22,811 | -4% | -$442,396 | ||||||
| D | 2026-03-02 | ARQT | Arcutis Biotherapeutics, Inc. | Leonard Keith R | Dir | S - Sale+OE | $25.39 | -39,272 | 23,873 | -62% | -$997,195 | |||||
2026-03-02 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $25.65 | -10,000 | 49,744 | -17% | -$256,518 | ||||||
2026-03-02 | AMLX | Amylyx Pharmaceuticals, Inc. | Klee Justin B. | Co-CEO | S - Sale | $14.47 | -29,282 | 3,334,616 | -1% | -$423,760 | ||||||
2026-03-02 | AMLX | Amylyx Pharmaceuticals, Inc. | Cohen Joshua B | Co-CEO | S - Sale | $14.48 | -29,282 | 3,334,683 | -1% | -$424,120 | ||||||
2026-03-02 | AMLX | Amylyx Pharmaceuticals, Inc. | Bedrosian Camille L | Chief Medical Officer | S - Sale | $14.58 | -6,461 | 169,295 | -4% | -$94,205 | ||||||
2026-03-02 | AMLX | Amylyx Pharmaceuticals, Inc. | Frates James M | CFO | S - Sale | $14.52 | -7,909 | 292,169 | -3% | -$114,851 | ||||||
2026-03-02 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $14.52 | -6,844 | 134,430 | -5% | -$99,378 | ||||||
| D | 2026-03-03 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $40.65 | -2,500 | 97,994 | -2% | -$101,620 | |||||
2026-03-02 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $42.19 | -15,000 | 642,540 | -2% | -$632,866 | ||||||
| D | 2026-03-02 | ARQT | Arcutis Biotherapeutics, Inc. | Edwards Larry Todd | See Remarks | S - Sale+OE | $25.18 | -3,687 | 175,178 | -2% | -$92,846 | |||||
| D | 2026-03-02 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale+OE | $25.18 | -37,349 | 1,019,091 | -4% | -$940,528 | |||||
| DM | 2026-02-27 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale+OE | $26.03 | -12,058 | 136,932 | -8% | -$313,877 | |||||
| D | 2026-03-02 | ARQT | Arcutis Biotherapeutics, Inc. | Vairavan Latha | SVP CFO | S - Sale+OE | $25.18 | -2,853 | 87,754 | -3% | -$71,844 | |||||
| D | 2026-03-02 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale+OE | $25.18 | -6,287 | 121,150 | -5% | -$158,320 | |||||
2026-03-02 | ABT | Abbott Laboratories | Shroff Eric | SVP | S - Sale | $115.58 | -709 | 39,164 | -2% | -$81,946 | ||||||
2026-03-02 | ABT | Abbott Laboratories | Salvadori Daniel Gesua Sive | EVP, GROUP Pres | S - Sale | $115.58 | -885 | 146,377 | -1% | -$102,288 | ||||||
2026-03-02 | ABT | Abbott Laboratories | Morrone Louis H. | EVP | S - Sale | $115.58 | -1,144 | 76,855 | -1% | -$132,224 | ||||||
2026-03-02 | GNLX | Genelux Corp | Thomas John | Dir | S - Sale | $2.90 | -10,000 | 482,784 | -2% | -$28,957 | ||||||
2026-03-02 | ABT | Abbott Laboratories | Moreland Mary K | EVP | S - Sale | $115.58 | -613 | 116,136 | -1% | -$70,851 | ||||||
2026-03-02 | ABT | Abbott Laboratories | McCoy John A. Jr. | VP, CONTROLLER | S - Sale | $115.58 | -585 | 24,686 | -2% | -$67,614 | ||||||
2026-03-02 | ABT | Abbott Laboratories | Cushman Elizabeth C. | EVP, GC, SECRETARY | S - Sale | $115.58 | -263 | 38,573 | -1% | -$30,398 | ||||||
2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Pinion John Richard | See Remarks | S - Sale | $22.80 | -10,029 | 110,026 | -8% | -$228,661 | ||||||
2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Officer | S - Sale | $22.80 | -10,539 | 89,515 | -11% | -$240,289 | ||||||
2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Kakkis Emil D | Pres, CEO | S - Sale | $22.80 | -54,404 | 2,817,979 | -2% | -$1,240,411 | ||||||
2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | EVP, GC | S - Sale | $22.80 | -8,135 | 76,346 | -10% | -$185,478 | ||||||
2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Huizenga Theodore Alan | SVP, Chief Accounting Officer | S - Sale | $22.80 | -1,632 | 48,670 | -3% | -$37,210 | ||||||
| M | 2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $22.65 | -10,044 | 85,034 | -11% | -$227,538 | |||||
2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Crombez Eric | EVP, Chief Medical Officer | S - Sale | $22.80 | -7,029 | 76,301 | -8% | -$160,261 | ||||||
2026-03-02 | ABBV | Abbvie Inc. | Siatis Perry C | EVP, GC, SECRETARY | S - Sale | $234.39 | -18,668 | 4,619 | -80% | -$4,375,549 | ||||||
2026-03-03 | ANIP | Ani Pharmaceuticals Inc | Walsh Patrick D | Dir | S - Sale | $74.23 | -6,000 | 52,405 | -10% | -$445,380 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |